Mabwell's MAIWEIJIAN Denosumab Gets NMPA Acceptance for Expanded Cancer Bone Treatment

Key Takeaways

• China’s NMPA has accepted Mabwell’s supplemental biologics license application for MAIWEIJIAN (denosumab) to expand treatment indications
• The expanded indication targets prevention of skeletal-related events in multiple myeloma patients and those with bone metastases from solid tumors
• This regulatory milestone positions Mabwell’s T-mab subsidiary to compete in China’s growing oncology bone health market

---

NMPA Accepts Mabwell’s Expanded Denosumab Application

Mabwell (688062.SH) announced on April 15, 2026, that China’s National Medical Products Administration (NMPA) has accepted a supplemental Biologics License Application for MAIWEIJIAN (denosumab injection, R&D code: 9MW0321). The application seeks approval for preventing skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors.

Expanding Treatment Options for Cancer Patients

The acceptance represents a significant regulatory milestone for Mabwell’s wholly-owned subsidiary T-mab. MAIWEIJIAN, the company’s denosumab biosimilar, could provide Chinese oncologists with an additional treatment option for managing bone complications in cancer patients.

Denosumab works by inhibiting RANKL (Receptor Activator of Nuclear factor Kappa-Β Ligand), a protein that promotes bone destruction. This mechanism makes it particularly valuable for cancer patients experiencing bone metastases or multiple myeloma, conditions that frequently cause painful skeletal complications.

Market Impact and Competitive Landscape

China’s oncology market continues expanding rapidly, with bone health treatments representing a growing segment. The NMPA’s acceptance of Mabwell’s supplemental application demonstrates the regulatory body’s commitment to increasing treatment access for cancer patients.

Mabwell’s integrated biopharmaceutical approach, spanning the full industry chain, positions the company to capitalize on this opportunity. The company’s established manufacturing capabilities and regulatory experience could accelerate market entry once approval is granted.

Next Steps in the Approval Process

Following NMPA acceptance, Mabwell will work through the standard review process for supplemental biologics applications. The timeline for final approval will depend on the agency’s review of clinical data supporting the expanded indications.

This development reinforces Mabwell’s strategy of expanding its oncology portfolio while leveraging existing biosimilar platforms to address unmet medical needs in China’s healthcare system.

---

Frequently Asked Questions

What does this NMPA acceptance mean for cancer patients?

The acceptance brings Mabwell’s MAIWEIJIAN denosumab closer to approval for preventing bone complications in multiple myeloma and solid tumor patients, potentially providing more treatment options.

When will MAIWEIJIAN be available for these new indications?

The timeline depends on NMPA’s review process for the supplemental application. No specific approval date has been announced following this acceptance milestone.

How does MAIWEIJIAN compare to existing bone health treatments?

MAIWEIJIAN is a denosumab biosimilar that works by inhibiting RANKL to prevent bone destruction, similar to reference denosumab products but potentially at a more accessible price point.